SCHEMBL22011936

SCHEMBL22011936

NS(=O)(=NC(=O)Nc1c2c(cc3c1CCC3)CCC2)c1ccc(C2CCCN2)cc1

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 14/20 0.41
GSTO1 P78417 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30244076 1.00 NLRP3 (0.41) NLRP3GSTO1
SCHEMBL26978395 1.00 NLRP3 (0.41) NLRP3GSTO1
SCHEMBL26977686 1.00 NLRP3 (0.41) NLRP3GSTO1
SCHEMBL30244238 1.00 NLRP3 (0.41) NLRP3GSTO1
SCHEMBL25033919 0.94 NLRP3 (0.42) NLRP3GSTO1
SCHEMBL30243977 0.94 NLRP3 (0.42) NLRP3GSTO1
SCHEMBL25033894 0.94 NLRP3 (0.42) NLRP3GSTO1
SCHEMBL21962760 0.94 NLRP3 (0.42) NLRP3GSTO1
SCHEMBL25033698 0.94 NLRP3 (0.42) NLRP3GSTO1
SCHEMBL25033964 0.82 NLRP3 (0.40) NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-16 US disclosed
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-16 US disclosed
WO-2020102576-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 NLRP3 2/4885GSTO1 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.